Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Hoth Therapeutics, Inc. - SIC # 3840 -
Ticker
Exchange
SIC #
Website
Latest Ticker
HOTH
Nasdaq
3840
hoththerapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Hoth Therapeutics, Inc.
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
- Jan 24th, 2025 1:29 pm
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications
- Jan 21st, 2025 1:29 pm
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025
- Jan 17th, 2025 1:29 pm
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
- Jan 9th, 2025 6:48 pm
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries
- Jan 8th, 2025 6:27 pm
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal
- Jan 8th, 2025 3:41 pm
Hoth Therapeutics Soars 215% on Breakthrough Cancer Treatment Success
- Jan 7th, 2025 7:10 pm
Top Midday Gainers
- Jan 7th, 2025 6:29 pm
Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities
- Jan 7th, 2025 1:29 pm
Top Midday Decliners
- Dec 26th, 2024 6:05 pm
Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment
- Dec 26th, 2024 12:58 pm
MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000
- Nov 22nd, 2024 5:25 pm
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study
- Oct 29th, 2024 4:43 pm
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway
- Oct 15th, 2024 10:38 am
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ
- Sep 17th, 2024 11:57 am
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient
- Sep 6th, 2024 2:43 pm
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
- Sep 5th, 2024 2:32 pm
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001
- Sep 5th, 2024 12:03 pm
Hoth and Aronnax partner for HT-KIT cancer therapy development
- Aug 16th, 2024 10:33 am
Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic
- Aug 15th, 2024 12:04 pm
Scroll